Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings. CMC change-control owner in a labeling team facing a boxed-warning debate has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences FDA Response and Labeling file.

DECISION CMC change-control owner in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. The population in disproportionate reporting signal workbook is the one an AdCom briefing document that overstates subgroup findings named, so Proceed under protocol follows for this FDA Response and Labeling file. 2. The population in disproportionate reporting signal workbook is adjacent only to an AdCom briefing document that overstates subgroup findings; Pause the pathway is the honest Pharma & Life Sciences call. 3. A labeling team facing a boxed-warning debate already contained an AdCom briefing document that overstates subgroup findings before disproportionate reporting signal workbook arrived; no new FDA Response and Labeling path. 4. Provenance on disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether disproportionate reporting signal workbook supports the labeled claim CMC change-control owner would keep. 3. Map FDA-response timing and owner in a labeling team facing a boxed-warning debate. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read disproportionate reporting signal workbook against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to drop a secondary for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings). The follow-on FDA Response and Labeling action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in disproportionate reporting signal workbook, then the action for CMC change-control owner - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Missing page in disproportionate reporting signal workbook after an AdCom briefing document that overstates subgroup findings, if any - Regulatory or exam hook FDA Response and Labeling would cite